A 64-year-old woman with osteoarthritis presents to the emergency room with a 2-day history of nausea and vomiting. Over the past few weeks, the patient has been taking painkillers to control worsening knee pain. Physical examination reveals scleral icterus and tender hepatomegaly. The patient appears confused. Laboratory investigations reveal the following enzyme levels:
Serum alanine aminotransferase (ALT) 845 U/L
Aspartate aminotransferase (AST) 798 U/L
Alkaline phosphatase 152 U/L
Which of the following is the most appropriate antidote for the toxicity seen in this patient?
Q42
A 45-year-old man comes to the physician because of numbness and tingling in his fingers and toes for the past month. He also describes difficulty with balance while walking. Laboratory studies show a hemoglobin concentration of 9.5 g/dL. Serum homocysteine and methylmalonic acid levels are elevated. Peripheral blood smear shows hypersegmented neutrophils. Which of the following is most likely to have prevented this patient's condition?
Q43
A 54-year-old woman presents to the emergency department with sudden shortness of breath. A CT scan shows multiple nodules in her left lung. She reports that for the past 6 months, she has been feeling tired and depressed. She also has frequently felt flushed, which she presumed is a symptom of getting closer to menopause. On physical examination, a nodule with a size of 2.5 cm is palpable in the left lobe of the thyroid gland; the nodule is firm and non-tender. Cervical lymphadenopathy is present. Cytology obtained by fine needle aspiration indicates a high likelihood of thyroid carcinoma. Laboratory findings show a serum basal calcitonin of 620 pg/mL. A thyroidectomy is performed but the patient presents again to the ER with flushing and diarrhea within 6 weeks. Considering this patient, which of the following treatment options should be pursued?
Q44
A 35-year-old woman comes to the physician because of a 3-month history of headache, palpitations, diarrhea, and weight loss. She takes no medications. Her pulse is 110/min and blood pressure is 125/70 mm Hg. Examination shows warm, moist skin and diffuse hyperreflexia. An MRI of the brain shows a sellar mass. The underlying cause of this patient's condition is best explained by binding of a ligand to which of the following?
Q45
A 58-year-old woman with type 2 diabetes mellitus comes to the physician because of a 3-month history of right lower extremity pain and burning while walking. The pain subsides with rest. She has smoked one pack of cigarettes daily for the past 30 years. Her current medications include metformin, atorvastatin, and aspirin. Examination shows a lack of hair and decreased skin temperature over the right foot. The right pedal pulse is not palpable. The physician adds a drug to her regimen that causes vasodilation and inhibits the aggregation of platelets and the proliferation of smooth muscle cells. Which of the following drugs was most likely added?
Q46
A newborn male, delivered by emergency Cesarean section during the 28th week of gestation, has a birth weight of 1.2 kg (2.5 lb). He develops rapid breathing 4 hours after birth. Examination of the respiratory system reveals a respiratory rate of 80/min, expiratory grunting, intercostal and subcostal retractions with nasal flaring. His chest radiograph shows bilateral diffuse reticulogranular opacities and poor lung expansion. His echocardiography suggests a diagnosis of patent ductus arteriosus with left-to-right shunt and signs of fluid overload. The pediatrician administers intravenous indomethacin to facilitate closure of the duct. Which of the following effects best explains the mechanism of action of this drug in the management of this neonate?
Q47
A 39-year-old man comes to the physician because of a 3-month history of fatigue, decreased sexual desire, and difficulty achieving an erection. He has no past medical history except for a traumatic brain injury he sustained in a motor vehicle accident 4 months ago. At that time, neuroimaging studies showed no abnormalities. Physical examination shows bilateral gynecomastia and a thin white nipple discharge. Decreased production of which of the following is the most likely underlying cause of this patient's current condition?
Q48
A 64-year-old man presents to the emergency department with acute onset of chest pain. He says the pain is substernal and radiates to his left arm. He has a history of hypertension, diabetes mellitus, erectile dysfunction, benign prostate hyperplasia, and panic disorder. He takes aspirin, lisinopril, metformin, sildenafil, prazosin, and citalopram. An electrocardiogram shows new ST-elevations in the lateral leads. He undergoes catherization, which reveals a complete blockage of the left circumflex artery. A stent is placed, and the patient is discharged with clopidogrel and isosorbide mononitrate. Five days later the patient presents to the emergency department complaining of fainting spells. The patient’s temperature is 97°F (37.2°C), blood pressure is 89/53 mmHg, and pulse is 90/min. Physical examination is unremarkable. An electrocardiogram reveals lateral Q waves without ST or T wave abnormalities. Which of the following is the most likely cause of the patient’s presentation?
Q49
A 27-year-old woman comes to her primary care physician complaining of palpitations. She reports that for the past 2 months she has felt anxious and states that her heart often feels like it’s “racing.” She also complains of sweating and unintentional weight loss. Physical examination reveals symmetrical, non-tender thyroid enlargement and exophthalmos. After additional testing, the patient is given an appropriate treatment for her condition. She returns 2 weeks later complaining of worsening of her previous ocular symptoms. Which of the following treatments did the patient most likely receive?
Q50
A 56-year-old male with history of CHF presents to a trauma center following a motor vehicle accident. On arrival, his Glasgow Coma Scale score is 8, and he is found to have increased intracranial pressure. Mannitol is administered. Which of the following side effects of the drug would you most likely observe in this patient?
Autonomic/CV Drugs US Medical PG Practice Questions and MCQs
Question 41: A 64-year-old woman with osteoarthritis presents to the emergency room with a 2-day history of nausea and vomiting. Over the past few weeks, the patient has been taking painkillers to control worsening knee pain. Physical examination reveals scleral icterus and tender hepatomegaly. The patient appears confused. Laboratory investigations reveal the following enzyme levels:
Serum alanine aminotransferase (ALT) 845 U/L
Aspartate aminotransferase (AST) 798 U/L
Alkaline phosphatase 152 U/L
Which of the following is the most appropriate antidote for the toxicity seen in this patient?
A. N-acetylmuramic acid
B. N-acetyl-p-benzoquinoneimine
C. N-acetylcysteine (Correct Answer)
D. N-acetylaspartic acid
E. N-acetylglucosamine
Explanation: ***N-acetylcysteine***
- The patient's presentation with nausea, vomiting, confusion, scleral icterus, tender hepatomegaly, and significantly elevated **ALT** and **AST** levels (in the hundreds) after taking painkillers strongly suggests **acetaminophen (paracetamol) toxicity** leading to acute liver failure.
- **N-acetylcysteine (NAC)** is the specific antidote for acetaminophen overdose; it works by replenishing hepatic **glutathione** stores, which are crucial for detoxifying the toxic metabolite **N-acetyl-p-benzoquinone imine (NAPQI)**.
*N-acetylmuramic acid*
- This compound is a component of **bacterial cell walls** and is not involved in human metabolism or toxicology.
- It has no role as an antidote for drug-induced liver injury or any known human toxicity.
*N-acetyl-p-benzoquinoneimine*
- This is the highly reactive and **toxic metabolite of acetaminophen (NAPQI)** that causes liver damage when glutathione stores are depleted.
- It is the substance that NAC helps to detoxify, not an antidote itself.
*N-acetylaspartic acid*
- This molecule is concentrated in the **brain** and is involved in neuronal osmoregulation and energy metabolism.
- It is not an antidote for drug toxicity and is primarily associated with neurological conditions like Canavan disease.
*N-acetylglucosamine*
- This is a **monosaccharide derivative** involved in the biosynthesis of glycoproteins and proteoglycans.
- It has no established role as an antidote for acetaminophen toxicity or any other acute poisoning.
Question 42: A 45-year-old man comes to the physician because of numbness and tingling in his fingers and toes for the past month. He also describes difficulty with balance while walking. Laboratory studies show a hemoglobin concentration of 9.5 g/dL. Serum homocysteine and methylmalonic acid levels are elevated. Peripheral blood smear shows hypersegmented neutrophils. Which of the following is most likely to have prevented this patient's condition?
A. Folic acid supplementation
B. Avoidance of lead-based paint
C. Cyanocobalamin supplementation (Correct Answer)
D. Avoidance of canned foods
E. Pyridoxine supplementation
Explanation: ***Cyanocobalamin supplementation***
- The patient's symptoms (numbness, tingling, difficulty with balance, anemia) and lab findings (**elevated homocysteine** and **methylmalonic acid**, **hypersegmented neutrophils**) are classic for **vitamin B12 deficiency**.
- **Cyanocobalamin** is vitamin B12, and supplementation would prevent the development of these signs and symptoms.
*Folic acid supplementation*
- While folic acid deficiency also causes **macrocytic anemia** and **elevated homocysteine**, it does not lead to elevated methylmalonic acid or the neurological symptoms described.
- Supplementing folic acid without addressing vitamin B12 deficiency can mask the hematological signs of B12 deficiency while allowing neurological damage to progress.
*Avoidance of lead-based paint*
- **Lead poisoning** can cause anemia and neurological symptoms (e.g., peripheral neuropathy), but it typically presents with microcytic or normocytic anemia, not macrocytic anemia, and would not cause elevated methylmalonic acid.
- Hypersegmented neutrophils are not characteristic of lead poisoning.
*Avoidance of canned foods*
- **Botulism** (often associated with improperly canned foods) causes neurological symptoms like paralysis but does not cause anemia or elevated homocysteine and methylmalonic acid.
- It's an acute toxin-mediated illness, not a deficiency state.
*Pyridoxine supplementation*
- **Pyridoxine (vitamin B6) deficiency** can cause microcytic anemia (sideroblastic anemia), peripheral neuropathy, and cheilosis and glossitis, but it would not lead to macrocytic anemia, elevated methylmalonic acid, or hypersegmented neutrophils.
- Elevated homocysteine can occur but is not as characteristic as in B12 or folate deficiency.
Question 43: A 54-year-old woman presents to the emergency department with sudden shortness of breath. A CT scan shows multiple nodules in her left lung. She reports that for the past 6 months, she has been feeling tired and depressed. She also has frequently felt flushed, which she presumed is a symptom of getting closer to menopause. On physical examination, a nodule with a size of 2.5 cm is palpable in the left lobe of the thyroid gland; the nodule is firm and non-tender. Cervical lymphadenopathy is present. Cytology obtained by fine needle aspiration indicates a high likelihood of thyroid carcinoma. Laboratory findings show a serum basal calcitonin of 620 pg/mL. A thyroidectomy is performed but the patient presents again to the ER with flushing and diarrhea within 6 weeks. Considering this patient, which of the following treatment options should be pursued?
A. Observation
B. Tamoxifen
C. Vandetanib (Correct Answer)
D. Radioactive iodine (radioiodine)
E. Thyroid-stimulating hormone (TSH) suppression
Explanation: ***Vandetanib***
- This patient's presentation with **thyroid nodule**, **elevated calcitonin**, and symptoms like flushing and diarrhea, combined with lung metastases, is highly suggestive of **medullary thyroid carcinoma (MTC)**. The recurrence of flushing and diarrhea post-thyroidectomy indicates **persistent or metastatic disease**.
- **Vandetanib** is a multi-kinase inhibitor specifically approved for the treatment of **symptomatic or progressive medullary thyroid carcinoma** that is unresectable or metastatic. It targets key pathways involved in MTC proliferation and angiogenesis, offering a systemic treatment option for advanced disease.
*Observation*
- **Observation** is not appropriate for metastatic medullary thyroid carcinoma, especially given the patient's persistent and symptomatic disease with lung metastases and systemic symptoms.
- MTC is an aggressive cancer, and untreated metastatic disease would lead to continued progression and worsening symptoms.
*Tamoxifen*
- **Tamoxifen** is a selective estrogen receptor modulator primarily used in the treatment of **estrogen receptor-positive breast cancer**.
- It has no role or efficacy in the treatment of medullary thyroid carcinoma.
*Radioactive iodine (radioiodine)*
- **Radioactive iodine (RAI) therapy** is effective for differentiated thyroid cancers (papillary and follicular) because these cancers retain the ability to absorb iodine.
- **Medullary thyroid carcinoma** originates from parafollicular C cells and does not take up iodine, rendering RAID therapy ineffective.
*Thyroid-stimulating hormone (TSH) suppression*
- **TSH suppression therapy** is used in differentiated thyroid cancers to reduce the growth stimulus provided by TSH, thereby reducing recurrence risk.
- **Medullary thyroid carcinoma** does not arise from TSH-dependent thyroid follicular cells, so TSH suppression therapy is not effective for MTC.
Question 44: A 35-year-old woman comes to the physician because of a 3-month history of headache, palpitations, diarrhea, and weight loss. She takes no medications. Her pulse is 110/min and blood pressure is 125/70 mm Hg. Examination shows warm, moist skin and diffuse hyperreflexia. An MRI of the brain shows a sellar mass. The underlying cause of this patient's condition is best explained by binding of a ligand to which of the following?
A. Nonreceptor tyrosine kinase
B. Intracytosolic nuclear receptor
C. Receptor tyrosine kinase
D. Membrane-bound guanylate cyclase
E. G protein-coupled receptors (Correct Answer)
Explanation: ***G protein-coupled receptors***
- The patient's symptoms (tachycardia, diarrhea, weight loss, warm moist skin, hyperreflexia) are highly suggestive of **hyperthyroidism**. The sellar mass on MRI points to a **TSH-secreting pituitary adenoma (secondary hyperthyroidism)**, which leads to excessive activation of **TSH receptors** on thyroid follicular cells.
- TSH receptors are a classic example of **G protein-coupled receptors**. When TSH binds, it activates an associated G protein, leading to an intracellular signaling cascade (typically through adenylyl cyclase and cAMP) that stimulates thyroid hormone synthesis and release.
*Nonreceptor tyrosine kinase*
- This class of receptors (e.g., for **cytokines** like growth hormone or interferons) often involves **JAK-STAT pathways** and does not typically mediate the effects of TSH.
- While involved in various cellular processes, they are not the primary mechanism by which TSH exerts its effects on the thyroid gland.
*Intracytosolic nuclear receptor*
- **Steroid hormones** (like cortisol, estrogen, testosterone) and **thyroid hormones (T3/T4)** themselves bind to intracytosolic or nuclear receptors, which then translocate to the nucleus to regulate gene transcription.
- TSH, being a polypeptide hormone, cannot directly cross the cell membrane to bind to an intracytosolic receptor; it acts via a cell-surface receptor.
*Receptor tyrosine kinase*
- These receptors (e.g., for **insulin** or **growth factors** like EGF, PDGF) directly possess intrinsic tyrosine kinase activity or are tightly associated with one upon ligand binding.
- While they mediate many growth and metabolic effects, TSH signaling primarily occurs through G protein-coupled receptors, not receptor tyrosine kinases.
*Membrane-bound guanylate cyclase*
- This type of receptor, such as the receptor for **atrial natriuretic peptide (ANP)**, directly catalyzes the formation of **cGMP** upon ligand binding.
- While other membrane-bound receptors exist, the TSH receptor specifically functions as a G protein-coupled receptor linked to the adenylyl cyclase system, not directly activating guanylate cyclase.
Question 45: A 58-year-old woman with type 2 diabetes mellitus comes to the physician because of a 3-month history of right lower extremity pain and burning while walking. The pain subsides with rest. She has smoked one pack of cigarettes daily for the past 30 years. Her current medications include metformin, atorvastatin, and aspirin. Examination shows a lack of hair and decreased skin temperature over the right foot. The right pedal pulse is not palpable. The physician adds a drug to her regimen that causes vasodilation and inhibits the aggregation of platelets and the proliferation of smooth muscle cells. Which of the following drugs was most likely added?
A. Cilostazol (Correct Answer)
B. Bosentan
C. Eptifibatide
D. Dabigatran
E. Clopidogrel
Explanation: ***Cilostazol***
- **Cilostazol** is a **phosphodiesterase-3 (PDE3) inhibitor** approved specifically for the treatment of **intermittent claudication**, a symptom of peripheral arterial disease (PAD).
- Its mechanism of action involves **vasodilation** via increased cAMP and **inhibition of platelet aggregation** and smooth muscle cell proliferation.
*Bosentan*
- **Bosentan** is an **endothelin receptor antagonist** used primarily for the treatment of **pulmonary arterial hypertension**.
- Its main effect is **vasodilation** in the pulmonary vasculature, and it is not indicated for peripheral arterial disease.
*Eptifibatide*
- **Eptifibatide** is a **glycoprotein IIb/IIIa inhibitor** that primarily blocks the final common pathway of **platelet aggregation**, used in acute coronary syndromes or during PCI.
- It does not significantly promote vasodilation and is not a first-line treatment for chronic symptoms of PAD.
*Dabigatran*
- **Dabigatran** is a **direct thrombin inhibitor** used to prevent stroke in atrial fibrillation and to treat/prevent deep vein thrombosis and pulmonary embolism.
- While it inhibits coagulation, it does not exert significant vasodilatory effects or directly modify smooth muscle cell proliferation in the context of PAD.
*Clopidogrel*
- **Clopidogrel** is a **P2Y12 platelet inhibitor** that prevents platelet aggregation, often used for acute coronary syndromes, stroke prevention, and in PAD.
- While it effectively inhibits platelet aggregation, it does not have significant vasodilatory properties that would directly alleviate claudication symptoms by increasing blood flow.
Question 46: A newborn male, delivered by emergency Cesarean section during the 28th week of gestation, has a birth weight of 1.2 kg (2.5 lb). He develops rapid breathing 4 hours after birth. Examination of the respiratory system reveals a respiratory rate of 80/min, expiratory grunting, intercostal and subcostal retractions with nasal flaring. His chest radiograph shows bilateral diffuse reticulogranular opacities and poor lung expansion. His echocardiography suggests a diagnosis of patent ductus arteriosus with left-to-right shunt and signs of fluid overload. The pediatrician administers intravenous indomethacin to facilitate closure of the duct. Which of the following effects best explains the mechanism of action of this drug in the management of this neonate?
A. Increased synthesis of prostaglandin E2
B. Inhibition of cyclooxygenase (Correct Answer)
C. Decreased blood flow in the vasa vasorum of the ductus arteriosus
D. Induction of endothelial nitric oxide synthase
E. Increased synthesis of platelet-derived growth factor (PDGF)
Explanation: ***Inhibition of cyclooxygenase***
- **Indomethacin** is a potent **cyclooxygenase (COX) inhibitor** (both COX-1 and COX-2), which is the primary mechanism for PDA closure in neonates.
- COX inhibition leads to **decreased synthesis of prostaglandin E2 (PGE2)**, which normally maintains ductal patency in utero.
- With reduced PGE2 levels, the **ductal smooth muscle constricts**, leading to closure of the patent ductus arteriosus.
- This is the standard mechanism taught for indomethacin use in PDA closure and is well-established in **neonatal pharmacology**.
*Decreased blood flow in the vasa vasorum of the ductus arteriosus*
- While decreased blood flow in the vasa vasorum may occur as a **secondary consequence** of prolonged ductal constriction, this is not the primary mechanism of action of indomethacin.
- The immediate pharmacological effect is **COX inhibition and PGE2 reduction**, not a direct effect on vasa vasorum blood flow.
- This represents a downstream anatomical consequence rather than the drug's mechanism of action.
*Induction of endothelial nitric oxide synthase*
- **Nitric oxide** is a potent vasodilator that would promote ductal patency, not closure.
- Indomethacin does not induce nitric oxide synthase; its action is to **inhibit prostaglandin synthesis** through COX inhibition.
- This would have the opposite therapeutic effect.
*Increased synthesis of prostaglandin E2*
- **PGE2 maintains ductal patency** during fetal life by causing smooth muscle relaxation.
- Increasing PGE2 would **prevent closure** and worsen the PDA—this is the opposite of the desired effect.
- Indomethacin **decreases** PGE2 synthesis, not increases it.
*Increased synthesis of platelet-derived growth factor (PDGF)*
- While PDGF plays a role in vascular remodeling and long-term structural changes, it is not the mechanism by which indomethacin acutely closes the ductus arteriosus.
- The primary action is **prostaglandin inhibition**, not growth factor modulation.
- PDGF changes are not a significant acute effect of indomethacin therapy.
Question 47: A 39-year-old man comes to the physician because of a 3-month history of fatigue, decreased sexual desire, and difficulty achieving an erection. He has no past medical history except for a traumatic brain injury he sustained in a motor vehicle accident 4 months ago. At that time, neuroimaging studies showed no abnormalities. Physical examination shows bilateral gynecomastia and a thin white nipple discharge. Decreased production of which of the following is the most likely underlying cause of this patient's current condition?
A. Gonadotropin-releasing hormone
B. Thyrotropin-releasing hormone
C. Luteinizing hormone
D. Growth hormone
E. Dopamine (Correct Answer)
Explanation: ***Dopamine***
- The patient's symptoms (fatigue, decreased sexual desire, erectile dysfunction, gynecomastia, galactorrhea) following a **traumatic brain injury (TBI)** are indicative of **hypopituitarism**, specifically affecting dopamine's inhibitory control over prolactin.
- **Dopamine** is produced in the hypothalamus and tonically inhibits **prolactin secretion** from the anterior pituitary; a decrease in dopamine can lead to elevated prolactin, causing the observed symptoms.
*Gonadotropin-releasing hormone*
- While TBI can cause **hypogonadism** due to GnRH deficiency, this would primarily lead to decreased LH/FSH and subsequent low testosterone, causing sexual dysfunction but not necessarily **galactorrhea** or **gynecomastia**.
- Decreased GnRH would result in low levels of LH and FSH, but the direct cause of gynecomastia and nipple discharge in this case is likely **hyperprolactinemia**.
*Thyrotropin-releasing hormone*
- TRH stimulates TSH release; a deficiency would lead to **central hypothyroidism** (fatigue, cold intolerance, weight gain), but it does not directly explain **gynecomastia** or **galactorrhea**.
- While TRH can stimulate prolactin secretion, a primary TRH deficiency would more prominently feature symptoms of hypothyroidism, which are not mentioned as the primary concern.
*Luteinizing hormone*
- A decrease in LH would lead to **decreased testosterone production** and symptoms like low sexual desire and erectile dysfunction. However, it does not directly cause **galactorrhea** or **gynecomastia** as seen in this patient.
- LH primarily acts on Leydig cells to produce testosterone; while low testosterone can cause gynecomastia, the nipple discharge points more strongly to **hyperprolactinemia**.
*Growth hormone*
- Growth hormone deficiency in adults can cause fatigue, decreased muscle mass, and central obesity but is not typically associated with **gynecomastia** or **galactorrhea**.
- A decrease in GH does not explain the breast-related symptoms observed in this patient.
Question 48: A 64-year-old man presents to the emergency department with acute onset of chest pain. He says the pain is substernal and radiates to his left arm. He has a history of hypertension, diabetes mellitus, erectile dysfunction, benign prostate hyperplasia, and panic disorder. He takes aspirin, lisinopril, metformin, sildenafil, prazosin, and citalopram. An electrocardiogram shows new ST-elevations in the lateral leads. He undergoes catherization, which reveals a complete blockage of the left circumflex artery. A stent is placed, and the patient is discharged with clopidogrel and isosorbide mononitrate. Five days later the patient presents to the emergency department complaining of fainting spells. The patient’s temperature is 97°F (37.2°C), blood pressure is 89/53 mmHg, and pulse is 90/min. Physical examination is unremarkable. An electrocardiogram reveals lateral Q waves without ST or T wave abnormalities. Which of the following is the most likely cause of the patient’s presentation?
A. Stent thrombosis
B. Fibrinous pericarditis
C. Myocardial wall rupture
D. Papillary muscle rupture
E. Medication interaction (Correct Answer)
Explanation: ***Medication interaction***
- The patient experienced **hypotension and fainting spells** after being prescribed **isosorbide mononitrate** (a nitrate) following his myocardial infarction. The patient also takes **sildenafil** (a PDE5 inhibitor) for erectile dysfunction, which when combined with nitrates can lead to severe and prolonged hypotension.
- Both **nitrates and sildenafil mediate nitric oxide (NO)-induced vasodilation**, leading to a synergistic effect on blood pressure reduction which caused his syncopal episodes.
*Stent thrombosis*
- This would typically present with a **recurrence of acute chest pain, ST-elevations, and signs of myocardial ischemia** due to re-occlusion of the stented artery.
- The patient's symptoms are primarily **fainting spells and hypotension**, without signs of recurrent ischemia on ECG (lateral Q waves indicate prior infarction, but no acute changes).
*Fibrinous pericarditis*
- This complication typically occurs **2-4 days post-MI** and presents with **pleuritic chest pain that is positional** (worse when lying flat, better when leaning forward) and can be associated with a pericardial friction rub.
- The patient's primary complaint is fainting spells and hypotension, not pleuritic chest pain.
*Myocardial wall rupture*
- A myocardial wall rupture is a catastrophic complication that typically presents with **sudden severe chest pain, profound hypotension, and often rapid death** due to cardiac tamponade.
- The patient's presentation of fainting spells without acute severe chest pain or immediate life-threatening collapse makes complete myocardial wall rupture less likely.
*Papillary muscle rupture*
- This complication primarily presents with acute onset of **severe mitral regurgitation**, leading to **acute pulmonary edema, dyspnea, and cardiogenic shock**.
- While hypotension can be present, the dominant symptoms are usually respiratory distress and signs of heart failure, which are not described in this patient's fainting spells.
Question 49: A 27-year-old woman comes to her primary care physician complaining of palpitations. She reports that for the past 2 months she has felt anxious and states that her heart often feels like it’s “racing.” She also complains of sweating and unintentional weight loss. Physical examination reveals symmetrical, non-tender thyroid enlargement and exophthalmos. After additional testing, the patient is given an appropriate treatment for her condition. She returns 2 weeks later complaining of worsening of her previous ocular symptoms. Which of the following treatments did the patient most likely receive?
A. Radioactive iodine (Correct Answer)
B. Propranolol
C. Methimazole
D. Propylthiouracil
E. Thyroidectomy
Explanation: ***Radioactive iodine***
- The constellation of **palpitations, anxiety, racing heart, sweating, unintentional weight loss, symmetrical non-tender thyroid enlargement**, and **exophthalmos** points to **Graves' disease**.
- This treatment is known to exacerbate ophthalmopathy due to the release of thyroid antigens following radiation-induced thyroid cellular damage, triggering an immune response.
*Propranolol*
- **Propranolol** is a **beta-blocker** used to manage the adrenergic symptoms of hyperthyroidism (e.g., palpitations, tremors, anxiety) but does not treat the underlying thyroid overproduction.
- It would not worsen ocular symptoms, as it primarily targets cardiovascular effects.
*Methimazole*
- **Methimazole** is an **antithyroid drug** that inhibits thyroid hormone synthesis and would improve both systemic and ocular symptoms over time by reducing the hyperthyroid state.
- It is a primary treatment for Graves' disease and would generally lead to improvement rather than worsening of symptoms.
*Propylthiouracil*
- **Propylthiouracil (PTU)** is another **antithyroid drug** that inhibits thyroid hormone synthesis and also blocks the conversion of T4 to T3.
- Similar to methimazole, PTU would alleviate hyperthyroid symptoms, including ocular manifestations, and not worsen them.
*Thyroidectomy*
- **Thyroidectomy** removes the thyroid gland, effectively treating hyperthyroidism and reducing the immune response over time.
- While it can sometimes be associated with a transient worsening of ophthalmopathy in some patients, it is less common and less pronounced than with radioactive iodine, and the long-term goal is improvement.
Question 50: A 56-year-old male with history of CHF presents to a trauma center following a motor vehicle accident. On arrival, his Glasgow Coma Scale score is 8, and he is found to have increased intracranial pressure. Mannitol is administered. Which of the following side effects of the drug would you most likely observe in this patient?
A. Pulmonary edema (Correct Answer)
B. Seizures
C. Restrictive cardiomyopathy
D. Arrhythmias
E. Blood dyscrasias
Explanation: ***Pulmonary edema***
- **Mannitol** is an osmotic diuretic that initially draws fluid from the interstitial space into the intravascular compartment, causing **transient hypervolemia** before diuresis occurs.
- In patients with **congestive heart failure (CHF)**, the heart has limited ability to handle this acute increase in preload, making **pulmonary edema the most likely complication** during mannitol administration.
- This is a well-recognized risk that requires careful monitoring, especially in patients with compromised cardiac function. The fluid overload can precipitate acute decompensation before the diuretic effect provides relief.
- Mannitol should be used cautiously in CHF patients, with slow administration and close monitoring of volume status.
*Arrhythmias*
- While mannitol can cause electrolyte disturbances (**hypokalemia**, **hyponatremia**, or **hyperkalemia** from renal effects) that may precipitate arrhythmias, this is less immediately likely than pulmonary edema.
- Electrolyte shifts typically develop over time with repeated dosing or in the setting of renal dysfunction, rather than as an acute complication after initial administration.
- CHF patients may be more susceptible to arrhythmias from electrolyte imbalances, but this is not the most immediate concern.
*Seizures*
- Seizures are not a typical direct side effect of mannitol administration.
- They can result from the underlying **cerebral edema** or neurological injury that mannitol is being used to treat.
- Rarely, **rebound cerebral edema** from rapid osmotic shifts or very high doses could theoretically worsen neurological status, but seizures are not a recognized direct adverse effect.
*Blood dyscrasias*
- **Blood dyscrasias** (disorders affecting blood cell production or function) are not associated with mannitol.
- This adverse effect is characteristic of medications affecting **bone marrow function**, such as chemotherapeutic agents or certain antibiotics.
*Restrictive cardiomyopathy*
- **Restrictive cardiomyopathy** is a chronic structural heart disease characterized by impaired ventricular filling due to rigid myocardium.
- This is not an acute side effect of mannitol, which primarily affects **fluid and electrolyte balance** without causing structural cardiac changes.